Pacific Biosciences of Californ vs UnitedHealth Group Incorporated — Stock Comparison
Q·Score Breakdown
5.5
Neutral
Overall
6.3
Neutral
Quality
Health
Growth
Valuation
Sentiment
PACB
Revenue expanding at 14% year-over-year.
⚠ low return on equity (-213%).
UNH
82% of 28 covering analysts have a positive rating.
⚠ limited growth momentum.
Analyst Consensus
HOLD
Target $2.38 (+48.4%)
6 analysts
BUY
Target $387.27 (+5.0%)
26 analysts
Fundamentals
PACB
UNH
—
Trailing P/E
27.9×
-3.8×
Forward P/E
17.8×
0.0%
Profit Margin
2.7%
34.3%
Gross Margin
18.8%
-213.5%
ROE
12.2%
13.8%
Revenue Growth
2.0%
—
Earnings Growth
0.7%
2.33
Beta
0.41
—
Price / Book
—
$497M
Market Cap
$334.9B
$1 – $3
52-Week Range
$235 – $410
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →